154 related articles for article (PubMed ID: 22694113)
1. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer.
Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD
Am J Manag Care; 2012 May; 18(5):e186-93. PubMed ID: 22694113
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer.
Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD
J Oncol Pract; 2012 May; 8(3 Suppl):e31s-7s. PubMed ID: 22942832
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
[TBL] [Abstract][Full Text] [Related]
5. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
Yu JB; Cramer LD; Herrin J; Soulos PR; Potosky AL; Gross CP
J Clin Oncol; 2014 Apr; 32(12):1195-201. PubMed ID: 24616315
[TBL] [Abstract][Full Text] [Related]
7. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
Konski A; Watkins-Bruner D; Feigenberg S; Hanlon A; Kulkarni S; Beck JR; Horwitz EM; Pollack A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):408-15. PubMed ID: 16887291
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China.
Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN
BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957
[TBL] [Abstract][Full Text] [Related]
11. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed.
Carter HE; Martin A; Schofield D; Duchesne G; Haworth A; Hornby C; Sidhom M; Jackson M
Radiother Oncol; 2014 Aug; 112(2):187-93. PubMed ID: 24929702
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
[TBL] [Abstract][Full Text] [Related]
14. Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective?
Vanneste BG; Pijls-Johannesma M; Van De Voorde L; van Lin EN; van de Beek K; van Loon J; Ramaekers BL; Lambin P
Radiother Oncol; 2015 Feb; 114(2):276-81. PubMed ID: 25616537
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer.
Yong JH; Beca J; McGowan T; Bremner KE; Warde P; Hoch JS
Clin Oncol (R Coll Radiol); 2012 Sep; 24(7):521-31. PubMed ID: 22705100
[TBL] [Abstract][Full Text] [Related]
16. A response to Sher et al, "Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer".
Collins SP; Suy S; Chen LN; Collins BT; Dritschilo A
Am J Clin Oncol; 2013 Jun; 36(3):316-7. PubMed ID: 23681018
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer.
Zemplényi AT; Kaló Z; Kovács G; Farkas R; Beöthe T; Bányai D; Sebestyén Z; Endrei D; Boncz I; Mangel L
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 26782759
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.
Kim H; Vargo JA; Beriwal S; Clump DA; Ohr JP; Ferris RL; Heron DE; Huq MS; Smith KJ
Head Neck; 2018 Aug; 40(8):1743-1751. PubMed ID: 29537684
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.
Parthan A; Pruttivarasin N; Davies D; Taylor DC; Pawar V; Bijlani A; Lich KH; Chen RC
Front Oncol; 2012; 2():81. PubMed ID: 22934286
[TBL] [Abstract][Full Text] [Related]
20. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
Konski A; Speier W; Hanlon A; Beck JR; Pollack A
J Clin Oncol; 2007 Aug; 25(24):3603-8. PubMed ID: 17704408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
